Comparison 19. Head‐to‐head comparisons.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
19.1 Drop‐out rate due to treatment emergent adverse effects	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
19.1.1 Reboxetine versus fluvoxamine	1	40	Risk Ratio (M‐H, Random, 95% CI)	0.65 [0.42, 1.00]
19.2 Clinician administered scales: Symptom severity	4		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only
19.2.1 Nefazodone versus sertraline	2	80	Std. Mean Difference (IV, Random, 95% CI)	‐0.19 [‐0.63, 0.25]
19.2.2 Venlafaxine versus sertraline	1	352	Std. Mean Difference (IV, Random, 95% CI)	‐0.01 [‐0.22, 0.20]
19.2.3 Reboxetine versus fluvoxamine	1	28	Std. Mean Difference (IV, Random, 95% CI)	0.67 [‐0.11, 1.45]
19.3 Comorbid symptoms: Depression	2		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only
19.3.1 Nefazodone versus sertraline	1	26	Std. Mean Difference (IV, Random, 95% CI)	‐0.09 [‐0.86, 0.68]
19.3.2 Reboxetine versus fluvoxamine	1	28	Std. Mean Difference (IV, Random, 95% CI)	0.67 [‐0.11, 1.45]
19.4 Comorbid symptoms: Anxiety (Hamilton Anxiety Scale)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
19.4.1 Nefazodone versus sertraline	1	26	Mean Difference (IV, Random, 95% CI)	‐3.23 [‐10.90, 4.44]
19.4.2 Reboxetine versus fluvoxamine	1	28	Mean Difference (IV, Random, 95% CI)	1.80 [‐1.30, 4.90]